| Name | Title | Contact Details |
|---|---|---|
Andrew Quant |
Sr. Director of Information Security and Compliance | Profile |
At South Carolina Federal Credit Union, we connect remarkable people with exceptional opportunities. We are passionate about exceeding expectations and providing "Life Simplified" experiences for our members, and were are proud to be an Employer of Choice organization where people matter. Weve been selected 11 times as one of the Best Places to Work in SC, six times as one of the Best Credit Unions to Work For nationally, and were currently on Glassdoors coveted Best Places to Work list for the fifth time. Our core values of honesty, teamwork, professionalism, positivity, and accountability, coupled with our ability to share the vision, help us to stand out as leaders within the financial services industry. We offer a full range of financial services, including savings and investments, checking, credit cards, and loans. We offer a personable environment, with convenience unsurpassed in our area. Credit union membership is ownership. We are not-for-profit and exist only for the financial benefit of our members. As a result, South Carolina Federal is able to pay competitive dividends on savings and offer attractive interest rates on loans. We invite you to visit our website to learn more... www.scfederal.org.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Icreon is a leading customer experience transformation company providing organizations with digital strategy consulting, design, and engineering services at scale. Founded in 2000 and headquartered in New York with offices in London and New Delhi, Icreon specializes in serving Fortune 500 clients including industry leaders like Johnson Controls, Acrisure, Jets.com to the Major League Baseball Players Association. Fortune 500 companies, growing brands, and non-profits partner with Icreon to enable their next phase of growth through digital.
The WSAVA represents more than 200,000 veterinarians worldwide through its 110 member associations and works to enhance standards of clinical care for companion animals. Its core activities include the development of WSAVA Global Guidelines in key areas of companion animal veterinary practice and lobbying on important issues affecting companion animal care worldwide.